Blockchain

3DOS Launching Decentralized “Uber for 3D Printing” on Sui

Grand Cayman, Cayman Islands, September 12th, 2024, Chainwire

3DOS chooses Sui as the exclusive blockchain partner to power its global decentralized peer-to-peer manufacturing network

Sui, a cutting-edge Layer 1 blockchain, announced a strategic alliance with 3DOS™, a leading innovator in decentralized manufacturing. The alliance promises to solve the coordination problems plaguing the $15.6 trillion global manufacturing market by coupling 3DOS’s expansive network of 3D printers, manufacturers, and customers with Sui’s advanced decentralized blockchain technologies. Sui’s industry-first zkLogin technology will make onboarding new users particularly easy for 3DOS by natively allowing millions of people to access the service using traditional social accounts like Google or Twitch.

Prior to engaging with Sui, the 3DOS founders pioneered one of the world’s first 3D printing operating systems and achieved remarkable results. So far, the platform has over 500,000 users, has manufactured 4.2 million parts, and has supported more than 15 million CAD designs across 120+ countries. Customers include John Deere, Google, MIT, Harvard, CalTech, UC Berkeley, Bosch, the British Army, the US Navy, the US Air Force, and NASA. These customers are currently being onboarded onto the network that 3DOS™ is building on Sui.

A heat map of 3DOS’s decentralized infrastructure, which is now migrating to the SUI Mainnet, with over 24,000 3D Printed NFT’s minted within a week since launch. Data as of Sept 9, 2024

The current partnership adds to 3DOS the redundancy, transparency, speed, and flexibility inherent in leveraging Sui’s industry-leading decentralized technology platform.

“At 3DOS, we believe that manufacturing should be decentralized. By tapping Sui to power our infrastructure, we now have the technology to enable this massive shift in our industry,” said John Dogru, Founder and CEO of 3DOS. “3DOS is a 3D Operating System, bridging the digital world to the physical world, allowing anyone to access manufacturing capacity and 3D printers anywhere empowering local producers and eliminating waste, inventory, and the carbon footprint associated with international shipping.”

Together, the technological innovations of the Sui and 3DOS combination will enable the massive global manufacturing industry to harness the power of localized production and eliminate the inefficiencies of high operational costs, and limited accessibility that currently plague it. The 3DOS/Sui solution addresses these continuing challenges and also vastly expands the world’s manufacturing potential by connecting siloed 3D printing capacity to massive demand around the world. In the process, the partners’ decentralized approach will reduce costs, democratize manufacturing, and open up new economic opportunities globally.

“Improving manufacturing processes is one of the world’s most important challenges, and the infrastructure that 3DOS is building on Sui marks a significant advancement that will catalyze economic growth and technological innovation,” said Adeniyi Abiodun, Chief Product Officer and Co-Founder of Mysten Labs which developed the Sui Network. “Through this partnership with 3DOS, Sui is helping to create a global decentralized manufacturing network that empowers more individuals and businesses to participate in the production of physical goods.”

The 3DOS platform leverages smart contracts on Sui to eliminate the overhead typically associated with coordinating supply and demand, which traditionally requires thousands of employees at Web2 companies and banks. By programming governing rules and processes directly into Sui’s blockchain, 3DOS achieves near-zero human intervention and infinite scalability. This approach optimizes resource efficiency and enhances supply chain transparency, reducing waste, improving cost-effectiveness, ensuring quality assurance, and facilitating global collaboration—all while empowering a diverse range of creators and innovators.

Contact

Sui Foundation
media@sui.io

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

2024-09-17T13:00:00Z

Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform

AMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube’s advanced AI platform. This effort is spearheaded by PersonalAIze CEOs and AI experts, Mark Hoogendoorn and Sandjai Bhulai, who bring their extensive expertise to assess the platform developed under the guidance of Frank van Asch, CTO and co-Founder of the technology on which RenovaroCube is based.

Prof. Mark Hoogendoorn, also a professor of Artificial Intelligence, expressed his enthusiasm: “We were pleased to be engaged to make an assessment of the AI platform; this is exactly the area of PersonalAIze’s expertise.”

Frank van Asch remarked on the collaboration, “The expertise of PersonalAIze’s team is exceptional, and their positive evaluation of our AI/ML platform is invaluable.”

RenovaroCube's AI platform has been advancing innovation for the past 12 years, evolving from its award-winning Fintech roots into a potentially groundbreaking multi-omic molecular differential system that identifies cancer in its earliest stages. It is an open platform that can be used as a SaaS by many private sector and academic or other large hospital and health systems. It is also disease agnostic, so it can be expanded for many purposes.

The initial aim is to transform cancer early detection and early detection of recurrence from a small vial of blood (liquid biopsy), potentially supporting clinicians to initiate treatments as soon as possible towards improved outcomes for patients.

In their analysis, PersonalAIze noted the platform's focus on liquid biopsies and third-generation sequencing coupled with AI techniques as highly promising, potentially allowing for comprehensive analysis across varying cancer types and stages. Prof. Sandjai Bhulai, also a professor of Mathematics, commented on the platform’s unique potential and the impressive multidisciplinary team at RenovaroCube under Frank van Asch’s leadership.

Based on these findings, PersonalAIze is eager to collaborate further with RenovaroCube to enhance and commercialize the platform.

PersonalAIze aims to contribute in several key areas:

  • Advancing AI models by leveraging the latest state-of-the-art techniques.
  • Supporting the professional growth of the software team.
  • Enhancing the explainability of AI models, engaging clinicians in model development.
  • Selecting optimal patient groups for data collection and evaluating models and final products in clinical settings.

This partnership could represent a substantial step forward in the fight against cancer, bringing together AI innovation and healthcare expertise to develop a powerful tool for early detection that has the potential to save countless lives.

About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.

About PersonalAIze
PersonalAIze focusses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision making systems as well as improvement of health care operations such as capacity planning.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For media inquiries, please contact: karen@renovarocube.com

Source: Renovaro Inc.


GlobeNewsWire News

Recent Comments